GLUE Monte Rosa Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GLUE

Price (delayed)

$11.89

Market cap

$1.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.76

Enterprise value

$957.32M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 24
Highlights
The quick ratio is up by 49% year-on-year and by 11% since the previous quarter
The debt has declined by 8% year-on-year and by 2.8% since the previous quarter
The equity has surged by 82% year-on-year but it has declined by 7% since the previous quarter
Monte Rosa Therapeutics's revenue has shrunk by 84% YoY and by 33% QoQ
The gross profit has dropped by 84% year-on-year and by 33% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of GLUE

GLUE stock price

How has the Monte Rosa Therapeutics stock price performed over time
Intraday
-5.63%
1 week
-6.01%
1 month
-16.85%
1 year
87.84%
YTD
-24.17%
QTD
-50.87%

Financial performance

How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$28.73M
Gross profit
$28.73M
Operating income
-$181.85M
Net income
-$161.12M
Gross margin
100%
Net margin
-560.9%
The net margin has dropped by 85% since the previous quarter
Monte Rosa Therapeutics's revenue has shrunk by 84% YoY and by 33% QoQ
The gross profit has dropped by 84% year-on-year and by 33% since the previous quarter
The operating margin has dropped by 83% since the previous quarter

Price vs fundamentals

How does GLUE's price correlate with its fundamentals

Growth

What is Monte Rosa Therapeutics's growth rate over time

Valuation

What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
2.06
P/S
42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.32
Monte Rosa Therapeutics's EPS has decreased by 19% from the previous quarter
The equity has surged by 82% year-on-year but it has declined by 7% since the previous quarter
GLUE's P/B is 32% below its last 4 quarters average of 3.2 but 9% above its 5-year quarterly average of 2.0
Monte Rosa Therapeutics's revenue has shrunk by 84% YoY and by 33% QoQ
GLUE's price to sales (P/S) is 29% more than its last 4 quarters average of 34.4

Efficiency

How efficient is Monte Rosa Therapeutics business performance
Monte Rosa Therapeutics's ROS has plunged by 86% from the previous quarter
Monte Rosa Therapeutics's ROA has decreased by 7% from the previous quarter
GLUE's ROE is down by 6% since the previous quarter
The ROIC has contracted by 2.3% from the previous quarter

Dividends

What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLUE.

Financial health

How did Monte Rosa Therapeutics financials performed over time
The total liabilities has surged by 123% year-on-year but it has declined by 5% since the previous quarter
GLUE's total assets has soared by 92% year-on-year but it is down by 6% since the previous quarter
The debt is 92% smaller than the equity
The equity has surged by 82% year-on-year but it has declined by 7% since the previous quarter
The debt to equity has contracted by 47% YoY but it has grown by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.